香港醫思醫療集團(02138.HK)擬發行可換股債券及認股權證
格隆匯 11 月 19日丨香港醫思醫療集團(02138.HK)發佈公告，2020年11月18日，公司訂立以下認購協議：(1)與GS訂立GS認購協議，據此，GS已有條件同意認購本金總額為2.34億港元的GS可換股債券及總額為2.73億港元的GS認股權證；(2)與OrbiMed訂立OrbiMed認購協議，據此，OrbiMed已有條件同意認購本金總額為3120萬港元的OrbiMed可換股債券及總額為3640萬港元的OrbiMed認股權證；(3)與GAW訂立GAW認購協議，據此，GAW已有條件同意認購本金總額為3900萬港元的GAW可換股債券。
倘可換股債券所附的換股權獲行使，而所有換股股份均分別按初步GS換股價每股換股股份5.69港元(就GS而言)；初步OrbiMed換股價每股換股股份5.69港元(就OrbiMed而言)；及初步GAW換股價每股換股股份5.21港元(就GAW而言)悉數轉換，則不多於4112.478萬股GS換股股份、548.3304萬股OrbiMed換股股份及748.5604萬股GAW換股股份(即合共約5409.37萬股換股股份)將予配發及發行，相當於該公告日期公司已發行股本總額約5.20%；及經配發及發行換股股份擴大後的公司已發行股本總數約4.94%。
倘認購權獲行使，所有認股權證股份均分別按初步認股權證認購價每股認股權證股份6.17港元悉數認購，則不多於4424.6353萬股GS認股權證股份及589.9513萬股OrbiMed認股權證股份(即合共約5014.59萬股認股權證股份)將予配發及發行，相當於該公告日期公司已發行股本總額約4.82%；及經配發及發行認股權證股份擴大後的公司已發行股本約4.60%。
假設分別按初步GS轉換價、初步OrbiMed轉換價及初步GAW轉換價以及初步認股權證認購價悉數行使可換股債券的換股權及認股權證的認購權，則合共約1.04億股新股份(包括5409.3688萬股換股股份及5014.5866萬股認股權證股份)將獲配發及發行，相當於公司現有已發行股本約10.02%；及經配發及發行換股股份及認股權證股份擴大後的公司已發行股本約9.11%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
